Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.97 USD

28.97
32,299,589

+0.04 (0.14%)

Updated Sep 26, 2024 04:00 PM ET

Pre-Market: $28.97 0.00 (0.00%) 9:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pfizer Inks New CAR-T Deal, In Talks With P&G for Unit Sale

Pfizer (PFE) out-licenses CAR-T assets to Allogene Therapeutics to expedite development. CNBC report says Pfizer in talks with P&G regarding sale of its Consumer Healthcare unit.

    The Zacks Analyst Blog Highlights: Facebook, UnitedHealth, Pfizer, McDonald's and MetLife

    The Zacks Analyst Blog Highlights: Facebook, UnitedHealth, Pfizer, McDonald's and MetLife

      The Zacks Analyst Blog Highlights: Pfizer, Unique Fabricating, Guess', Nordstrom and Ciner Resources

      The Zacks Analyst Blog Highlights: Pfizer, Unique Fabricating, Guess', Nordstrom and Ciner Resources

        Mark Vickery headshot

        Top Research Reports for Facebook, UnitedHealth & Pfizer

        Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), UnitedHealth (UNH) and Pfizer (PFE).

          Alnylam Falls on Pfizer's Rare Disease Drug Success

          Shares of Alnylam (ALNY) fall by more than 8% after Pfizer reports top-line results from the phase III study of tafamidis.

            Shire's Stock Continues to Rise as Takeda Sets Eyes On it

            Takeda expressed its intention to take over Shire (SHPG) to boost its geographic presence and product portfolio.

              Amgen's Blincyto Gets FDA Nod for Minimum Residual Disease

              Amgen's (AMGN) leukemia drug, Blincyto is the first approved drug for the treatment of minimal residual disease in the United States.

                Pfizer's Rare Disease Candidate Meets Endpoint in Phase III

                Pfizer's (PFE) pipeline candidate tafamidis, developed for the treatment of transthyretin cardiomyopathy (TTR-CM), meets the main goal in a late-stage study.

                  Tirthankar Chakraborty headshot

                  5 Juicy Dividend Stocks to Ride Out a Dicey April

                  April is historically the second best month of the year, but there are ample reasons why it could be cruel this year.

                    Tackle Market Uncertainty With These 3 Quality Dividend ETFs

                    Consider these three dividend ETFs for your portfolio to fight growing market uncertainty.

                      Indrajit Bandyopadhyay headshot

                      Is a Recession in the Cards? 4 Safe Bets for Your Portfolio

                      After nearly a decade of the global financial crisis of 2007-2008, some analysts believe that the threat of another recession lurks. However, the time and its impact is yet to be ascertained.

                        Merck KGaA's Tepotinib Gets Fast Track Designation in Japan

                        Merck KGaA's (MKGAF) lung cancer candidate, tepotinib gets fast track designation in Japan.

                          Glaxo (GSK) Buys Novartis' Stake in Consumer Healthcare JV

                          Glaxo (GSK) is buying out Novartis' stake in their Consumer Healthcare JV. Glaxo is also initiating a strategic review of its Horlicks business and its majority stake in Indian subsidiary.

                            Kinjel Shah headshot

                            4 Top-Ranked Drug/Biotech Stocks to Buy as Q1 Nears End

                            The first quarter of 2018 is drawing to a close. With the outlook optimistic for the rest of the year, we highlight four drug/biotech stocks worth buying

                              Pfizer's Chantix Fails in Phase IV Study in Young Smokers

                              Pfizer's (PFE) Chantix fails to meet primary endpoint in a phase IV study, a regulatory post-marketing commitment.

                                Glaxo Drops Bid for Pfizer Unit, Shingrix Gains EU/Japan Nod

                                Glaxo (GSK) withdraws from the process related to Pfizer's Consumer Health unit. Shingrix gains regulatory approval in Japan and EU.

                                  Tirthankar Chakraborty headshot

                                  Wall Street Braces for Ugliest March: 5 Ultra-Safe Picks

                                  The Dow is on track for its worst March in nearly 40 years, while the month is likely to be most awful for the S&P 500 and the Nasdaq since 2001.

                                    Novartis Gets Positive CHMP Opinion on Biosimilar Remicade

                                    The CHMP gave a positive opinion to Novartis (NVS) proposed biosimilar of Remicade for all of the branded drug's indications. A decision from the EMA is expected shortly.

                                      The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer

                                      The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer

                                        Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus

                                        Novartis' (NVS) Tasigna and Seattle Genetics' (SGEN) Adcetris receive regulatory approvals for label expansion. Pfizer's label expansion application for Xtandi gets priority review.

                                          Merck Gets European Committee Vote for Veterinary Product

                                          Merck (MRK) is seeking approval of Bravecto Plus, a spot-on solution for cats. The drug is part of the company's Animal Health unit.

                                            4 Reasons Why Glaxo (GSK) Stock Can be a Great Pick in '18

                                            Glaxo (GSK) has a Zacks Rank #2 (Buy). Its shares have outperformed the industry this year so far. Earnings estimates are also on the rise.

                                              Pfizer's Xtandi Label Expansion Filing Gets Priority Review

                                              FDA grants priority review status to Pfizer's(PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.

                                                J&J Gets $2.1B Offer for LifeScan Diabetes Device Unit

                                                J&J (JNJ) receives an offer for its LifeScan unit from private firm, Platinum Equity. It has time until Jun 15 to accept the offer, failing which it will expire.

                                                  Should Value Investors Pick Pfizer (PFE) Stock Now?

                                                  Let's see if Pfizer Inc. (PFE) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.